Nanotechnology Now - Press Release: Moving diagnostics out of the lab and into your hand: Electrochemical sensor platform technology could enable portable, multiplexed, point-of-care diagnostics for a wide range of applications

Home > Press > Moving diagnostics out of the lab and into your hand: Electrochemical sensor platform technology could enable portable, multiplexed, point-of-care diagnostics for a wide range of applications

Central to eRapid’s success is an antifouling coating on top of the electrode that is permeated by conductive components. When a target (yellow) binds to its probe (purple), it attracts a secondary probe (magenta) that initiates the precipitation of a compound onto the electrode, generating an electrical signal that reports the concentration of the target molecule. Credit: Wyss Institute at Harvard University

Abstract:
Handheld electrochemical sensors are part of the daily routine for millions of people with diabetes around the globe who monitor their blood sugar levels with electric glucometers. While such sensors have revolutionized at-home medical testing for diabetics, they have not yet been successfully applied to diagnosing other conditions. Sensors like glucometers detect glucose in blood based on the activity of an enzyme, and there are only a limited number of enzymes that can be used to sense biomarkers of human disease. An alternative detection strategy based on binding events between antibodies and their molecular targets have been investigated to expand the use of electrochemical sensors for medicine, but these sensors fall victim to the rapid accumulation of "fouling" substances from biological fluids on their conductive surfaces, which deactivate them. Existing antifouling coatings are difficult to mass-manufacture, suffer from quality and consistency issues, and are not very effective.

Moving diagnostics out of the lab and into your hand: Electrochemical sensor platform technology could enable portable, multiplexed, point-of-care diagnostics for a wide range of applications

Cambridge, MA | Posted on November 11th, 2019

Now, a new diagnostic platform technology developed by researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University known as "eRapid" enables the creation of low-cost, handheld electrochemical devices that can simultaneously detect a broad range of biomarkers with high sensitivity and selectivity in complex biological fluids, using as little as a single drop of blood. The technology is described in the newest issue of Nature Nanotechnology.

"As long as an antibody exists for a given target molecule, eRapid can detect it," said co-author Pawan Jolly, Ph.D., a Senior Research Scientist at the Wyss Institute. "By solving the biofouling problem with a simple yet robust design, we are now able to easily mass-produce biochemical sensors for a wide variety of applications at low-cost."

The challenge in developing the antifouling coating was to prevent accumulation of off-target substances on the sensor's metal electrodes while still maintaining their conductivity to allow sensing of the target. After experimenting with a variety of recipes, the research team developed a simple, porous, 3D matrix consisting of bovine serum albumin (BSA) crosslinked with glutaraldehyde and supported by a network of conducting nanomaterials, such as gold nanowires or carbon nanotubes. The small pore size of the BSA matrix size-excludes proteins found in blood and plasma, and the BSA's weak negative charge prevents the strong adhesion of positively charged biomolecules onto the sensor.

When the researchers tested their nanomaterial-coated sensors in human blood serum and plasma, they retained more than 90% of their ability to detect signal even after being stored for one month in those biofluids, whereas sensors coated with best previously published anti-fouling coatings lost significant signal sensitivity when incubated for one hour, and were completely inactivated after one day.

To functionalize the coated sensors, the researchers attached antibodies to the surface of the nanomaterial coating on top of the electrode, and used a "sandwich assay" to convert the antibody binding event into a chemical signal that precipitates onto the electrode surface, thereby generating an electric signal. The magnitude of the electrical signal directly correlates to the amount of the precipitate produced, and thus to the number of target molecules bound to the antibodies, allowing the concentration of the target to be measured.

The team demonstrated the commercial utility of this approach by creating a multiplexed sensor with three separate electrodes, each coated with the BSA/gold nanowire matrix and a layer of antibodies against a specific clinically relevant target molecule: interleukin 6 (IL6), insulin, or glucagon. When they incubated the sensor with the respective target molecules in undiluted human plasma, they observed excellent electrical signals with picogram-per-mL sensitivity. Conversely, electrodes coated with a published "PEG-SAM" anti-fouling coating failed to produce distinct signals, indicating that they had been irreversibly fouled by off-target molecules in human plasma samples. In addition, the BSA/gold-nanowire-coated sensors can be washed and reused multiple times with minimal signal loss, allowing serial monitoring of biomarkers easily and at low cost.

Since then, the Wyss team has been able to detect more than a dozen different biomarkers ranging from 100 Da to 150,000 Da in size with eRapid, and they are continuing to experiment with conductive nanomaterials to optimize the electrode coating and the system's performance, as well as reduce the cost even further. They are actively exploring commercialization options for eRapid in the handheld point-of-care diagnostics space, but also hope to extend the coating and sensor technology platform to other targets and contexts, including in-hospital diagnostics, environmental toxin sensing, small molecule detection, and implantable medical devices.

Interestingly, the team - led by the Wyss Institute's Founding Director Donald Ingber, M.D., Ph.D. - did not originally set out with this goal in mind. This work began because they needed to simultaneously detect multiple biomolecules produced by various types of tissue cells growing within human Organs-on-Chips to non-invasively assess their function and inflammatory status over time. The tiny volume of liquid outflows from the chips' channels necessitated highly sensitive sensors that could also be multiplexed, which led to the creation of the current technology.

"eRapid emerged from pursuing one innovation that led to another that has the potential to transform medical diagnostics. Hopefully, this simple technology will enable great advances in our ability to develop handheld diagnostic devices that can be used at home, as well as in pharmacies, ambulances, doctor's offices, and emergency departments in the near future," said Ingber who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children's Hospital, and Professor of Bioengineering at Harvard's John A. Paulson School of Engineering and Applied Sciences.

###

Additional authors of the paper include former Wyss members Jonathan Sabaté del Río, Ph.D., who is currently a Postdoctoral Fellow at the Institute for Basic Science in Korea and Olivier Henry, Ph.D., who is currently a Program Manager at Imec in Belgium. This research was supported by the Wyss Institute for Biologically Inspired Engineering, the Defense Advanced Research Projects Agency, the Institute for Basic Science, the KeepSmilin4Abbie Foundation, and the National Science Foundation.

####

For more information, please click here

Contacts:
Lindsay Brownell
lindsay.brownell@wyss.harvard.edu
617-432-8266

@wyssinstitute

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: